This fat pitch is coming in hot ⚾🔥

Ten-bagger potential?                                                                                                                                                                                                                                                                                                                                                                                                                 October 10, 2023 This fat pitch is coming in hot ⚾🔥 *Sponsored by Sica Media Hey Folks, Jeff Bishop here again! On Friday, I went live to explain that my viewers weren’t imagining it – this is a difficult time to trade. Earlier in the week, I sent this email out to everyone since I was getting so many questions about betting against stocks right now. I know the tendency traders have to jump on the bandwagon when things are going south for the markets. They want to either sell everything near the bottom, or they want to get aggressive and start to bet against stocks when things look ugly. I think both of these are the wrong moves to make. At times like these, a single piece of news can cause many people to wind up on the wrong side of their trades, resulting in big correction days like we saw Friday. But that’s no reason to stay in the dugout. Instead, I argued that now’s the time to wait for what I call “fat pitches” to come along — high-confidence moves based on solid technicals. Well, folks, today I see one coming right over the plate. Let’s dig in… I first wrote to you about Swiss-based NLS Pharmaceutics (NASDAQ: NLSP) in late-August. As I wrote at the time, “We don’t often see setups like these so it is imperative to take full advantage when they do come around.” If you paid attention to that, you then witnessed NLSP make a double-digit move higher over the next week, before consolidating one more time, and ultimately making a clear breakout over 20% higher. Well folks, I’ve stayed tuned to the NLSP story since then and right now my favorite indicators are signaling that we may be on the cusp of another major breakout. Check this out: That’s the analysis of an advanced, computer-generated algorithm that considers over a dozen different momentum indicators to determine the most likely trend going forward. This “go/no go” algorithm is the single-best computer-generated indicator I look to for confirmation on when to enter a trade. When I layer it on top of my own indicators and analysis, it gives me a very high-level of confidence in my personal trading.. As you can see, I’ve highlighted several very quick and sizable recent gains… A 66% move in 4 days… a 40% move in a single day… a 22% move in 2 days… and a 42% move in 5 days… …And this is all just since June! In three of those reversals, you can see multiple, conflicting go/no-go markers along the trendline just before the chart legged up. These mixed signals are a classic indicator I’ve seen play out countless times before reversals. And that brings me to what I am seeing today. Those conflicting go/no-go markers suggest we could be very close to an inflection point, just like when I first alerted you to NLSP on August 22, before it made a 42% move higher. Looking at the chart of the last week, I’m not surprised those markers are flashing: As you can see, by the end of last week, NLSP was trading flat overall, but had tested new highs that were at least 10% moves up throughout the week. Yesterday morning kicked off with yet another 10% spike before settling in at recent support above $.70. This is often what the valley of a reversal will look like. Rarely will a stock rocket straight up at the end of a weeks-long drawdown. Instead, it will test the breakout repeatedly before making its ultimate swing. This is a great indication that an upside move is coming, and that it could be dramatic. For further confirmation, Yahoo! Finance is lighting up “bullish” on the slow stochastic oscillator, which you can read about in detail [here](. In brief, the slow stochastic helps us distinguish signal from noise by comparing the latest closing price to the highs and lows over the last 14 periods. This popular indicator is also giving a green light. Checking the news cycle, we just received [this report]( from Fintel last week: - The average one-year price target for NLS Pharmaceutics (NLSP) has been revised to $9.94 / share. This is an increase of 24.47% from the prior estimate of 7.99 dated August 31, 2023. - The price target is an average of many targets provided by analysts. The latest targets range from a low of 6.06 to a high of 14.18 / share. The average price target represents an increase of 1,286.84% from the latest reported closing price of 0.72 / share. That’s right, the average price target represents a 10-bagger opportunity 💰. Of course, since NLSP is a clinical-stage pharmaceutical company, a lot of that depends on the success of the company’s drug trials… In case you missed my earlier reports, NLSP is [on the cusp]( of its Phase 3 trial for its leading candidate, Mazindol ER, for treatment of narcolepsy. It has already received approval for the trial from the independent Institutional Review Board, and NLSP is attempting to speed approval by applying for a fast-track designation with the FDA. As the NLSP CEO noted in a letter to shareholders, “A medicine that receives Fast Track Designation can be on the market within six months of the regulatory application.” These things could be catalysts for a serious rocket-ride for the stock, but for our purposes, the current technical indicators are sufficient to suggest a big leg up in the near term. Will that happen for sure? The future is never certain in the markets. There is always risk. But as I said, based on my analysis, this is looking like a pitch right over the plate. You must do your own research, however. I’m mortal, after all, and I want all my readers to get used to studying charts, examining fundamentals, and ultimately making up their own minds. Nothing is ever guaranteed in life or trading, so make wise decisions that consider your own personal risk profile. I suggest first checking out the NLS Pharmaceutics website [here](, and especially browse through the [“Investors” page](. This is an opportunity that might be gone before you know it, so take the time to learn more about NLSP right now and see if it makes sense for you. From there, you’ll want to do an in-depth study of the stock’s chart. Again, the ticker is NLSP. Happy hunting! To Your Success, *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. Full Disclaimer Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. If you have a current active subscription with Jason Bond Picks you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at JasonBondPicks.com. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. Update your email preferences or unsubscribe [here]( © 2023 Jason Bond Picks 62 Calef Hwy. #233 Lee, NH 03861, United States of America